Dignify Therapeutics, DTI-117, FDA IND Clearance, Neurogenic Bowel Dysfunction, Phase 1 Clinical Trial, Neurological Disorders, NK2 Receptor Agonist

Research Triangle Park, North Carolina, U.S., October 7, 2026 Dignify Therapeutics, a biopharmaceutical development company focused on restoring bowel...